EFG International AG Invests $5.69 Million in Krystal Biotech, Inc. $KRYS

EFG International AG purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,304 shares of the company’s stock, valued at approximately $5,688,000. EFG International AG owned approximately 0.05% of Krystal Biotech at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. UMB Bank n.a. grew its holdings in Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares in the last quarter. Optimize Financial Inc raised its stake in shares of Krystal Biotech by 1.4% in the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after purchasing an additional 40 shares in the last quarter. Regal Investment Advisors LLC raised its stake in shares of Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock valued at $1,075,000 after purchasing an additional 44 shares in the last quarter. Torray Investment Partners LLC lifted its position in shares of Krystal Biotech by 0.4% during the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after purchasing an additional 47 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its stake in Krystal Biotech by 0.9% in the first quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company’s stock worth $1,537,000 after purchasing an additional 53 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 51,000 shares of company stock valued at $16,278,020. 13.10% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $356.19 on Wednesday. Krystal Biotech, Inc. has a one year low of $136.73 and a one year high of $382.54. The company has a 50-day simple moving average of $348.02 and a 200-day simple moving average of $302.59. The firm has a market capitalization of $10.54 billion, a PE ratio of 44.64 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Equities analysts forecast that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on KRYS. TD Cowen boosted their price objective on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, June 18th. HC Wainwright increased their target price on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a report on Tuesday, June 16th. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Finally, Bank of America upped their price target on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $365.40.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.